Skip to main content

Advertisement

Log in

Preparation and ocular pharmacokinetics of ganciclovir liposomes

  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

Ophthalmic liposomes of ganciclovir (GCV) were prepared by the reverse phase evaporation method, and their ocular pharmacokinetics in albino rabbits were compared with those obtained after dosing with GCV solution. The in vitro transcorneal permeability of GCV liposomes was found to be 3.9-fold higher than that of the solution. After in vivo instillation in albino rabbits, no difference was found in the precorneal elimination rate of GCV from liposome vs solution dosing. The aqueous humor concentration-time profiles of both liposomes and solution were well described by 2-compartmental pharmacokinetics with first-order absorption. The area under the curve of the aqueous humor concentration-time profiles of GCV liposomes was found to be 1.7-fold higher than that of GCV solution. Ocular tissue distribution of GCV from liposomes was 2 to 10 times higher in the sclera, cornea, iris, lens, and vitreous humor when compared with those observed after solution dosing. These results suggested that liposomes may hold some promise in ocular GCV delivery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Mar E, Cheng Y, Huang Y. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother, 1983;24:518–521.

    PubMed  CAS  Google Scholar 

  2. Martin J, Dvorack C, Smee D, Matthews T, Verheyden J, 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J Med Chem. 1983;26:759–761.

    Article  PubMed  CAS  Google Scholar 

  3. Cantrill H, Henry K, Melroe N, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results, Ophthalmology, 1989;96:367–374.

    PubMed  CAS  Google Scholar 

  4. Markham A, Faulde D. Ganciclovir: an update of its therapeutic use in cytomegalovirus infection, Drugs. 1994;48:455–460.

    Article  PubMed  CAS  Google Scholar 

  5. Maudgal P, De Clercq K, Descamps J, Missotten L. Topical treatment of experimental herpes simplex keratouveitis with 2′-O-glycylacyclovir, a water-soluble ester of acyclovir, Arch Opthalmol. 1984;102:140–142.

    CAS  Google Scholar 

  6. Hughes P, Mitra A. Effect of acylation on the ocular disposition of acyclovir. II. Corneal permeability and anti-HSV 1 activity of 29-esters in rabbit epithelial keratitis. J Ocul Pharmacol. 1993;9:299–309.

    Article  PubMed  CAS  Google Scholar 

  7. Drew W. Is combination antiviral therapy for CMV superior to monotherapy? J Clin Virol. 2006;35:485–488.

    Article  PubMed  CAS  Google Scholar 

  8. Wiltink E, Stekkinger P, Brakenhoff J, Danner S. Determination of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) in biological fluids by reverse-phase high pressure liquid chromatography. Pharm Weekbl Sci. 1987;9:261–264.

    PubMed  CAS  Google Scholar 

  9. Choonara Y, Pillay V, Carmichael T, et al. An in vitro study of the design and development of a novel doughnut-shaped minitablet for intraocular implantation. Int J Pharm. 2006;310:15–24.

    Article  PubMed  CAS  Google Scholar 

  10. Law S, Huang K, Chiang C. Acyclovir-containing liposomes for potential ocular delivery: corneal penetration and absorption. J Control Release. 2000;63:135–140.

    Article  PubMed  CAS  Google Scholar 

  11. Institute of Laboratory Animal Resources. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press, 1966.

    Google Scholar 

  12. Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA. 1978;75:4194–4198.

    Article  PubMed  CAS  Google Scholar 

  13. Wu P. The characterization and biodistribution of cefoxitin-loaded liposomes. Int J Pharm. 2004;271:31–39.

    Article  PubMed  CAS  Google Scholar 

  14. Law S, Hung H. Properties of acyclovir-containing liposomes for potential ocular delivery. Int J Pharm. 1998;161:253–259.

    Article  CAS  Google Scholar 

  15. Durrani A, Farr S, Kellaway I. Influence of molecular weight and formulation pH on the precorneal clearance rate of hyaluronic acid in the rabbit eye. Int J Pharm. 1995;118:243–250.

    Article  CAS  Google Scholar 

  16. McSharry J, McDonough A, Olson B, et al. Inhibition of ganciclovir-susceptible and-resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin Diagn Lab Immunol. 2001;8:1279–1281.

    Article  PubMed  CAS  Google Scholar 

  17. McCalden T, Levy M. Retention of topical liposomal formulation on the cornea. Experientia. 1990;46:713–715.

    Article  PubMed  CAS  Google Scholar 

  18. Pleyer U, Lutz S, Jusko W, et al. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci. 1993;34:2737–2742.

    PubMed  CAS  Google Scholar 

  19. Elsayed M, Abdallah O, Naggar V, et al. Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. Int J Pharm. 2006;322:60–66.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jiasheng Tu.

Additional information

Published: December 7, 2007

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shen, Y., Tu, J. Preparation and ocular pharmacokinetics of ganciclovir liposomes. AAPS J 9, 44 (2007). https://doi.org/10.1208/aapsj0903044

Download citation

  • Received:

  • Revised:

  • Accepted:

  • DOI: https://doi.org/10.1208/aapsj0903044

Keywords

Navigation